Rezultati pretrage - Arnob Banerjee

Detaljiziraj rezultate
  1. 1
    Effector, Memory, and Dysfunctional CD8<sup>+</sup>T Cell Fates in the Antitumor Immune Response

    Effector, Memory, and Dysfunctional CD8<sup>+</sup>T Cell Fates in the Antitumor Immune Response od John Reiser, Arnob Banerjee

    Izdano 2016
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  2. 2
    Micro‐RNA‐155 inhibits IFN‐γ signaling in CD4<sup>+</sup> T cells

    Micro‐RNA‐155 inhibits IFN‐γ signaling in CD4<sup>+</sup> T cells od Arnob Banerjee, Felix Schambach, Caitlin S. DeJong, Scott M. Hammond, Steven L. Reiner

    Izdano 2009
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  3. 3
    mTORC1 Promotes T-bet Phosphorylation To Regulate Th1 Differentiation

    mTORC1 Promotes T-bet Phosphorylation To Regulate Th1 Differentiation od Olesya Chornoguz, Robert S. Hagan, Azeb Haile, Matthew L. Arwood, Christopher Gamper, Arnob Banerjee, Jonathan D. Powell

    Izdano 2017
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  4. 4
    Cutting Edge: The Transcription Factor Eomesodermin Enables CD8+ T Cells To Compete for the Memory Cell Niche

    Cutting Edge: The Transcription Factor Eomesodermin Enables CD8+ T Cells To Compete for the Memory Cell Niche od Arnob Banerjee, Scott M. Gordon, Andrew M. Intlekofer, Michael Paley, Erin C. Mooney, Tulia Lindsten, E. John Wherry, Steven L. Reiner

    Izdano 2010
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  5. 5
    Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells

    Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells od Andrew M. Intlekofer, Naofumi Takemoto, Charlly Kao, Arnob Banerjee, Felix Schambach, John K. Northrop, Hao Shen, E. John Wherry, Steven L. Reiner

    Izdano 2007
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  6. 6
    Anomalous Type 17 Response to Viral Infection by CD8 <sup>+</sup> T Cells Lacking T-bet and Eomesodermin

    Anomalous Type 17 Response to Viral Infection by CD8 <sup>+</sup> T Cells Lacking T-bet and Eomesodermin od Andrew M. Intlekofer, Arnob Banerjee, Naofumi Takemoto, Scott M. Gordon, Caitlin S. DeJong, Haina Shin, Christopher A. Hunter, E. John Wherry, Tullia Lindsten, Steven L. Reiner

    Izdano 2008
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  7. 7
    Teclistamab: Mechanism of action, clinical, and translational science

    Teclistamab: Mechanism of action, clinical, and translational science od Yue Guo, Natalia A. Quijano Cardé, Lijuan Kang, Raluca Verona, Arnob Banerjee, Rachel Kobos, Katherine Chastain, Clarissa Uhlar, Kodandaram Pillarisetti, Margaret Doyle, Jennifer Smit, Nahor Haddish‐Berhane, Danièle Ouellet

    Izdano 2024
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  8. 8
    Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study

    Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study od Ajay K. Nooka, Cesar Rodriguez, María‐Victoria Mateos, Salomon Manier, Katherine Chastain, Arnob Banerjee, Rachel Kobos, Keqin Qi, Raluca Verona, Margaret Doyle, Thomas G Martin, Niels W.C.J. van de Donk

    Izdano 2023
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  9. 9
    S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY

    S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY od Fritz Offner, O. Decaux, Cyrille Hulin, Sébastien Anguille, Anne Sophie Michallet, Luciano J. Costa, Cyrille Touzeau, Kevin Boyd, Deeksha Vishwamitra, Yue Guo, Zhuolu Niu, Julie S. Larsen, Lingling Chen, Arnob Banerjee, Jenna D. Goldberg, Jeffrey Matous

    Izdano 2023
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  10. 10
    Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma

    Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma od Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Raluca Verona, Diego Vieyra, Tineke Casneuf, Damien Fink, Xin Miao, Yang Chen, Tara Stephenson, Arnob Banerjee, Brandi Hilder, Jeffery S. Russell, Jeffrey R. Infante, Yusri Elsayed, Jennifer Smit, Jenna D. Goldberg

    Izdano 2022
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  11. 11
    Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma

    Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma od Thomas G Martin, María‐Victoria Mateos, Ajay K. Nooka, Arnob Banerjee, Rachel Kobos, Lixia Pei, Ming Qi, Raluca Verona, Margaret Doyle, Jennifer Smit, Weili Sun, Danielle Trancucci, Clarissa Uhlar, Niels W.C.J. van de Donk, Cesar Rodriguez

    Izdano 2023
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  12. 12
    Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

    Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multip... od Deepu Madduri, Saad Z. Usmani, Sundar Jagannath, Indrajeet Singh, Enrique Zudaire, Tzu‐Min Yeh, Alicia J. Allred, Arnob Banerjee, Jeffrey L. Goldberg, Jordan M. Schecter, Sen Hong Zhuang, Jeffrey R. Infante, Syed Rizvi, Xiao-Hu Fan, Andrzej Jakubowiak, Jesús G. Berdeja

    Izdano 2019
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  13. 13
    Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma

    Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with r... od Tom Martin, Saad Z. Usmani, Jordan M. Schecter, Martin Vogel, Carolyn C. Jackson, William Deraedt, Hong Tian, Tzu‐Min Yeh, Arnob Banerjee, Lida Pacaud, Ashraf Garrett, Anja Haltner, Chris Cameron, Suzy Van Sanden, Joris Diels, Satish Valluri, Imtiaz A. Samjoo

    Izdano 2021
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  14. 14
    T-bet–dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow

    T-bet–dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow od Craig N. Jenne, Anselm Enders, Richard Rivera, Susan R. Watson, Alexander J. Bankovich, João P. Pereira, Ying Xu, Carla M. Roots, Joshua Beilke, Arnob Banerjee, Steven L. Reiner, Sara A. Miller, Amy S. Weinmann, Christopher C. Goodnow, Lewis L. Lanier, Jason G. Cyster, Jerold Chun

    Izdano 2009
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  15. 15
    Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)

    Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM) od Alfred L. Garfall, Saad Z. Usmani, María‐Victoria Mateos, Hareth Nahi, Niels W.C.J. van de Donk, Jesús F. San Miguel, Albert Oriol Rocafiguera, Laura Rosiñol, Ajai Chari, Manisha Bhutani, Lixia Pei, Raluca Verona, Suzette Girgis, Tara Stephenson, Jenna D. Goldberg, Arnob Banerjee, Amrita Krishnan

    Izdano 2020
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  16. 16
    Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1

    Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1 od Xin Miao, Liviawati S. Wu, Shun Xin Wang Lin, Yan Xu, Yang Chen, Yuki Iwaki, Rachel Kobos, Tara Stephenson, Kristy Kemmerer, Clarissa Uhlar, Arnob Banerjee, Jenna D. Goldberg, Danielle Trancucci, Amit Apte, Raluca Verona, Lixia Pei, Rachit Desai, Kathleen T. Hickey, Yaming Su, Danièle Ouellet, Mahesh N. Samtani, Yue Guo, Alfred L. Garfall, Amrita Krishnan, Saad Z. Usmani, Honghui Zhou, Suzette Girgis

    Izdano 2023
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  17. 17
    CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma

    CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma od Simon J. Harrison, Tamia Nguyen, Marzia Rahman, Jeremy Er, Jessica Li, Katherine Li, Nikoletta Lendvai, Jordan M. Schecter, Arnob Banerjee, Tito Roccia, Brad Foulk, Junchen Gu, Hao Zhao, Denis A. Smirnov, Ana Slaughter, Carolina Lonardi, Erin Lee, Loreta Marquez, Shirin Jadidi, Octavio Costa Filho, Nitin Patel, Dong Geng, Nicole M. Haynes, Hannah G. Kelly, Stephen Lade, Sean M. Grimmond, Piers Blombery

    Izdano 2023
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  18. 18
    Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study

    Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study od Diana Cortés‐Selva, Tatiana Perova, Sheri Skerget, Deeksha Vishwamitra, Sarah Stein, Rengasamy Boominathan, On Say Lau, Karl C. Nielsen, Cuc Davis, Jaymala Patel, Arnob Banerjee, Tara Stephenson, Clarissa Uhlar, Rachel Kobos, Jenna D. Goldberg, Lixia Pei, Danielle Trancucci, Suzette Girgis, Shun Xin Wang Lin, Liviawati S. Wu, Philippe Moreau, Saad Z. Usmani, Nizar J. Bahlis, Niels W.C.J. van de Donk, Raluca Verona

    Izdano 2024
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  19. 19
    Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation

    Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation od Kristine A. Frerichs, Christie P.M. Verkleij, María‐Victoria Mateos, Thomas G. Martin, Cesar Rodriguez, Ajay K. Nooka, Arnob Banerjee, Katherine Chastain, Alfredo Perales‐Puchalt, Tara Stephenson, Clarissa Uhlar, Rachel Kobos, Bronno van der Holt, Sandy Kruyswijk, Maria T. Kuipers, Kaz Groen, Deeksha Vishwamitra, Sheri Skerget, Diana Cortés‐Selva, Margaret Doyle, Hans L. Zaaijer, Sonja Zweegman, Raluca Verona, Niels W.C.J. van de Donk

    Izdano 2023
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  20. 20
    Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma

    Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Rela... od Thomas G. Martin, Saad Z. Usmani, Jesús G. Berdeja, Andrzej Jakubowiak, Mounzer Agha, Adam D. Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander M. Lesokhin, Nikhil C. Munshi, Elizabeth O’Donnell, A. Keith Stewart, Jordan M. Schecter, Jeffrey L. Goldberg, Carolyn C. Jackson, Tzu‐Min Yeh, Arnob Banerjee, Alicia J. Allred, Enrique Zudaire, William Deraedt, Deepu Madduri, Yunsi Olyslager, Changwei Zhou, Lida Pacaud, Yi Lin, Sundar Jagannath

    Izdano 2021
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:

Alati za pretragu: